BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Kalvista’s [in]Komplete study gives boost to Orladeyo blockbuster ambitions
Biocryst Pharmaceuticals Inc. caught some industry observers by surprise early in 2022 when it upped its peak sales estimate for Orladeyo (berotralstat), its oral therapy...

More in BioWorld

BioWorld MedTech

Multi Radiance shines with FDA clearance for laser treatment of fibromyalgia
Millions of patients with fibromyalgia have battled widespread pain with few effective treatment options for decades. The U.S. FDA has offered reason for hope and better...

More in BioWorld MedTech

BioWorld Science

Promoting attachments nets 2022’s Nobel Prize in Chemistry
The 2022 Nobel Prize in chemistry was awarded to Carolyn Bertozzi of Stanford University, to Morten Meldal of the University of Copenhagen, and – for the second time – to...

More in BioWorld Science

BioWorld Asia

Try again? $2.4B Sumitomo bid deemed low-ball as Myovant holds out for more
In what may just be the takeover effort’s first volley, Sumitovant Biopharma Ltd., a subsidiary of Sumitomo Pharma Co. Ltd., made a hefty offer for Myovant Sciences Ltd. –...

More in BioWorld Asia

BioWorld Insider Podcast

BioWorld staff writer Lee Landenberger talks with James Lanthier, the CEO of Mindset Pharma, which is developing what it calls “next-generation” psychedelic medicines to treat neurological and psychiatric disorders.